VEGFA and retinopathy of prematurity: The Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity study (BEAT-ROP) [13] showed that VEGF inhibitors have more satisfactory outcomes than laser photocoagulation in zone I ROP.